Open Beta
TREN
MetriLume
TREN

US marketsARCT

SEC-sourced researchBeta

ARCT

Arcturus Therapeutics Holdings Inc.

Company comparison ↗

Data passport

CIK
0001768224
Exchange
Nasdaq
Business activity
Pharmaceutical Preparations · SIC 2834
Financial inputs
6/6
Filing date
Sep 23, 2026
SEC registry record
Operating company
Last updated: SEC company ticker catalog ↗SEC Financial Statement Data Sets ↗SEC investment company series and class registry ↗

Annual financial history

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table. Exact amounts and source periods: December 2023: 166,799,000.0000 USD; December 2024: 152,310,000.0000 USD; December 2025: 82,031,000.0000 USD166.8M USD0 USD0December 2023December 2024December 2025
ARCT · Exact amounts and source periods · USD
Period endRevenueFiling date
December 2023166,799,000.0000Mar 3, 2026
December 2024152,310,000.0000Mar 3, 2026
December 202582,031,000.0000Mar 3, 2026

Annual periods · USD

Period endRevenueNet incomeOperating cash flowTotal assetsTotal liabilitiesFiling date
December 202582,031,000.0000-65,783,000.0000-74,271,000.0000271,148,000.000057,163,000.0000Mar 3, 2026
December 2024152,310,000.0000-80,941,000.0000-59,747,000.0000344,069,000.0000103,091,000.0000Mar 3, 2026
December 2023166,799,000.0000-29,725,000.0000-18,099,000.0000——Mar 3, 2026

Explainable fundamental score

Five equally weighted components based on SEC financial inputs. No price inputs or personal investment preferences.

37/100
Profitability0
Growth4
Balance sheet79
Cash generation0
Data coverage100

Component weight: 20% · Minimum data coverage: 50% · Missing component value: 50/100

Financial inputs behind the calculation

Financial inputsUSDPeriod endFiling dateForm
RevenueRevenueFromContractWithCustomerExcludingAssessedTax$82.03MJan 1, 2025 – Dec 31, 2025Mar 3, 202610-K
Previous period revenueRevenueFromContractWithCustomerExcludingAssessedTax$152.31MJan 1, 2024 – Dec 31, 2024Mar 3, 202610-K
Net incomeNetIncomeLoss-$65.78MJan 1, 2025 – Dec 31, 2025Mar 3, 202610-K
Operating cash flowNetCashProvidedByUsedInOperatingActivities-$74.27MJan 1, 2025 – Dec 31, 2025Mar 3, 202610-K
Total assetsAssets$271.15MDec 31, 2025Mar 3, 202610-K
Total liabilitiesLiabilities$57.16MDec 31, 2025Mar 3, 202610-K

New filings

Explore methodology ↗